NLRC4 and retinal ischemia: The production of NLRP3, NLRC4, and NLRP12 was all significantly lower in WT mice treated with CASP8 siRNA than in control mice, indicating that CASP8 exerted its inflammatory effect on retinal innate immunity by activating not only the classic NLRP3 but also the novel NLRP12 and NLRC4 in retinal ischemia (Fig. 6a and b).